Biel M L, Seus R, Struppler A
Med Klin. 1976 Dec 3;71(49):2177-84.
The efficacy of Hydergin was compared against placebo in a 15 weeks cross-over trial in 51 patients with cerebral insufficiency. The daily dosage was 3 mg of Hydergin. Criteria of evaluation consisted of clinical rating and electroencephalographic registrations, which were evaluated visually and partly automatically. The clinical symptoms as well as the electroencephalographic criteria (base line activity, theta- and delta activity) were both positively influenced by Hydergin. The base-line activity was stabilised and the alpha activity of the power spectrum increased. The most impressive result was the carryover effect of Hydergin, which could still be demonstrated in the post trial period. In case of "dizziness" the good results were limited to the period of active treatment. The relations between symptomatic and more basic therapy of cerebral insufficiency will be discussed.